Can turmeric ease ulcerative colitis pain. How does curcumin affect inflammation in ulcerative colitis. What does research say about turmeric’s effectiveness for IBD. How much turmeric is needed for potential benefits in ulcerative colitis. Are there any risks associated with using turmeric for ulcerative colitis.

The Healing Potential of Turmeric in Ulcerative Colitis

Turmeric, a golden spice deeply rooted in Asian cuisine and traditional medicine, has garnered attention for its potential therapeutic effects on inflammatory bowel diseases (IBD), including ulcerative colitis. The active compound responsible for turmeric’s reputed healing properties is curcumin, a phytochemical with anti-inflammatory, antioxidant, and immunosuppressive characteristics.

Recent studies have explored the efficacy of curcumin in managing ulcerative colitis symptoms, particularly when used in conjunction with conventional medications. While more extensive research is needed, initial findings suggest that curcumin may offer promise as a complementary therapy for individuals with mild to moderate ulcerative colitis.

Understanding Curcumin’s Role in Ulcerative Colitis Management

Curcumin, the active substance in turmeric, has been the subject of numerous studies investigating its potential benefits for ulcerative colitis patients. Research indicates that curcumin may help reduce inflammation in the colon, a key factor in managing ulcerative colitis symptoms.

How does curcumin work in the body?

Curcumin exerts its effects through multiple mechanisms:

• Reducing inflammation by inhibiting pro-inflammatory molecules
• Acting as an antioxidant to neutralize harmful free radicals
• Modulating the immune system to prevent excessive inflammatory responses

These properties make curcumin a potential ally in the management of ulcerative colitis, where chronic inflammation and immune dysfunction play significant roles.

Research Findings on Turmeric and Ulcerative Colitis

Several small-scale human trials have investigated the effects of curcumin supplementation in ulcerative colitis patients. These studies have provided encouraging results, suggesting that curcumin may enhance the effectiveness of conventional treatments.

Key research highlights:

• A 2015 study published in Clinical Gastroenterology & Hepatology found that patients taking mesalamine and 3,000 mg of curcumin daily achieved remission faster than those on mesalamine alone.
• A 2019 study in Phytotherapy Research reported that 1,500 mg of curcumin daily, combined with drug therapy, was associated with improved symptoms and quality of life in mild to moderate ulcerative colitis patients.
• A comprehensive review in the Annals of Gastroenterology (2020) concluded that patients using curcumin alongside mesalamine were three times more likely to experience symptom improvement compared to those on mesalamine alone.

While these findings are promising, larger clinical trials are necessary to establish a definitive role for curcumin in ulcerative colitis treatment.

Who Can Benefit from Turmeric Supplementation?

Based on current research, individuals with mild to moderate ulcerative colitis who are taking mesalamine may potentially benefit from adding curcumin to their treatment regimen. However, it’s important to note that the effectiveness of curcumin may vary among patients.

Is curcumin suitable for all ulcerative colitis patients?

While there is limited data on curcumin’s benefits for patients with severe ulcerative colitis, some healthcare professionals may not discourage its use if a patient expresses interest. It’s crucial to consult with a healthcare provider before incorporating curcumin or any new supplement into your treatment plan.

Optimal Turmeric Consumption for Potential Benefits

Determining the ideal amount of turmeric or curcumin for ulcerative colitis management can be challenging. The curcumin content in turmeric is relatively low, and the body does not readily absorb this compound.

How can you increase curcumin absorption?

To enhance the bioavailability of curcumin:

1. Combine turmeric with black pepper, as piperine (found in black pepper) can increase curcumin absorption by up to 2,000 percent.
2. Consider curcumin supplements, which often contain higher concentrations of the active compound.
3. Consume turmeric with healthy fats, as curcumin is fat-soluble.

While the optimal dosage of curcumin for ulcerative colitis is not yet established, incorporating turmeric into your diet may still offer some benefits.

Incorporating Turmeric into Your Diet

For those interested in increasing their turmeric intake through diet, there are numerous delicious ways to incorporate this golden spice into everyday meals.

Creative ways to add turmeric to your meals:

• Sprinkle turmeric on scrambled eggs or frittatas
• Season roasted vegetables with turmeric and black pepper
• Add turmeric to rice dishes for color and flavor
• Incorporate turmeric into curries and soups
• Blend turmeric into smoothies or golden milk
• Mix turmeric into oatmeal or yogurt

Remember to pair turmeric with black pepper and healthy fats to maximize its potential benefits.

Potential Risks and Considerations

While turmeric is generally considered safe for most people when consumed in food amounts, high doses or long-term use of curcumin supplements may cause side effects in some individuals.

What are the possible side effects of curcumin supplementation?

Potential side effects may include:

• Gastrointestinal discomfort
• Headaches
• Skin rashes
• Iron deficiency (in high doses)

It’s essential to consult with a healthcare provider before starting any new supplement regimen, especially if you have pre-existing health conditions or are taking medications.

The Future of Turmeric in Ulcerative Colitis Treatment

As research on turmeric and curcumin continues to evolve, the scientific community remains cautiously optimistic about their potential role in ulcerative colitis management. Ongoing studies aim to determine optimal dosages, long-term effects, and potential interactions with other treatments.

What developments can we expect in turmeric research?

Future research directions may include:

1. Larger-scale clinical trials to confirm preliminary findings
2. Studies on curcumin’s effectiveness in different stages of ulcerative colitis
3. Investigation of novel curcumin formulations for improved bioavailability
4. Exploration of curcumin’s potential in preventing ulcerative colitis flares

As our understanding of turmeric’s effects on ulcerative colitis grows, it may become an increasingly valuable tool in the management of this chronic condition.

Integrating Turmeric into a Comprehensive Ulcerative Colitis Management Plan

While turmeric shows promise as a complementary therapy for ulcerative colitis, it’s important to view it as part of a holistic approach to managing the condition. A comprehensive treatment plan typically involves a combination of medications, dietary modifications, stress management, and lifestyle adjustments.

How can turmeric complement other ulcerative colitis treatments?

Turmeric may enhance the effectiveness of conventional treatments by:

• Potentially reducing inflammation and supporting gut health
• Providing antioxidant benefits to combat oxidative stress
• Possibly helping to maintain remission when used alongside prescribed medications

It’s crucial to work closely with your healthcare team to develop a personalized treatment plan that may include turmeric or curcumin supplementation if deemed appropriate.

The Importance of Individualized Approaches in Ulcerative Colitis Care

Ulcerative colitis is a complex condition that affects individuals differently. What works for one person may not be as effective for another. This variability underscores the importance of personalized treatment strategies.

Why is a tailored approach crucial in ulcerative colitis management?

Individualized care is essential because:

1. Symptom severity and disease progression vary among patients
2. Dietary triggers and tolerances differ from person to person
3. Response to medications and supplements can be highly individual
4. Lifestyle factors and stress management needs are unique to each patient

When considering turmeric or any new treatment option, it’s important to assess its potential benefits and risks in the context of your specific health situation and treatment goals.

Monitoring and Adjusting Turmeric Use in Ulcerative Colitis

If you decide to incorporate turmeric or curcumin supplements into your ulcerative colitis management plan, it’s crucial to monitor your response and make adjustments as needed.

How should you track the effects of turmeric on your condition?

Consider the following strategies:

• Keep a detailed symptom journal to track changes in your condition
• Regularly communicate with your healthcare provider about any improvements or side effects
• Undergo periodic blood tests to monitor inflammation markers and overall health
• Be prepared to adjust dosage or discontinue use if advised by your doctor

Remember that the effects of turmeric may not be immediate, and it may take time to determine its impact on your ulcerative colitis symptoms.

The Role of Diet and Lifestyle in Conjunction with Turmeric Use

While turmeric may offer potential benefits for ulcerative colitis, it’s important to consider it as part of a broader approach to managing the condition. A healthy diet and lifestyle can complement the effects of turmeric and other treatments.

What dietary and lifestyle factors can support ulcerative colitis management?

Consider incorporating the following strategies:

1. Follow an anti-inflammatory diet rich in fruits, vegetables, and omega-3 fatty acids
2. Identify and avoid personal food triggers that may exacerbate symptoms
3. Engage in regular, gentle exercise to promote overall health and reduce stress
4. Practice stress-reduction techniques such as meditation or yoga
5. Ensure adequate sleep and rest to support your body’s healing processes

By combining turmeric use with these lifestyle modifications, you may be able to maximize its potential benefits and improve your overall quality of life with ulcerative colitis.

Can Turmeric Ease Ulcerative Colitis Pain?

The Indian spice, long prized for its medicinal and anti-inflammatory properties, may hold promise for people with ulcerative colitis.

By Ashley WelchMedically Reviewed by Lynn Grieger, RDN, CDCES

Reviewed: August 18, 2021

Medically Reviewed

Curcumin, which gives turmeric its golden color, may help reduce ulcerative colitis inflammation.Getty Images

Besides being a staple of Asian cuisine, turmeric has been used for centuries in Ayurvedic and traditional Chinese medicine to help treat a wide range of inflammatory diseases.

More recently, the spice has been associated with the treatment of irritable bowel diseases (IBD), including ulcerative colitis.

Turmeric’s potential healing powers come from curcumin, a phytochemical that is the active substance in turmeric, says the American Gastroenterological Association. Both turmeric and curcumin (on its own) are now sold widely as supplements.

While curcumin has been shown to have anti-inflammatory, antioxidant, and immunosuppressive properties, much of the research conducted to date has been in test tubes or animals.

A number of small human trials, however, have found that, when used with medication, curcumin may benefit people with mild to moderate ulcerative colitis.

“There isn’t enough evidence to show that curcumin can be helpful to every patient with IBD, but if we look at the data thus far and target specific patients, there may be some promise as a complementary therapy,” says Stacy Cavagnaro, RD, a dietitian at the Cleveland Clinic’s Inflammatory Bowel Disease Patient-Centered Medical Home.

What the Research Says About Turmeric for Ulcerative Colitis

One early study of 50 patients, published in 2015 in the journal Clinical Gastroenterology & Hepatology, found that patients taking mesalamine (a drug commonly used to treat mild to moderate ulcerative colitis) and 3,000 milligrams (mg) of curcumin via capsules achieved remission faster than those taking mesalamine and a placebo.

Another study, published in December 2019 in the journal Phytotherapy Research, which included 70 patients, found that 1,500 mg of curcumin per day, along with drug therapy, was associated with improvement of symptoms and overall quality of life in patients with mild to moderate ulcerative colitis.

In a comprehensive review published in January 2020 in the journal Annals of Gastroenterology, researchers gathered and analyzed all the human trials done on curcumin and ulcerative colitis to date. They found that patients using curcumin along with mesalamine were, on average, three times more likely to experience an improvement in symptoms than those who took mesalamine alone.

While these and other studies have shown promising results for the treatment of ulcerative colitis when used with drug therapy, trials with a larger number of people are needed to establish a clear role for curcumin, says the Crohn’s & Colitis Foundation.

Still, experts like Linda Antinoro, RD, a dietitian at Brigham and Women’s Hospital in Boston who works with patients with IBD, thinks it’s a tool that can help people with mild to moderate symptoms. “More and more doctors are putting turmeric in their repertoire to help treat ulcerative colitis,” she says.

RELATED: 12 Scientific Health Benefits of Turmeric and Curcumin

Which Ulcerative Colitis Patients Can Benefit From Turmeric?

According to trial data, if you have mild to moderate ulcerative colitis and you’re taking mesalamine, adding curcumin to your regimen might help you get to remission sooner, says Cavagnaro.

And while there is no data to show curcumin is beneficial to patients with severe ulcerative colitis, she wouldn’t dissuade one of her patients from trying it.

“I can’t point to data that it certainly works, but I also can’t point to data that it doesn’t work,” Cavagnaro says. “While there isn’t enough evidence for this type of patient, if they are interested in trying curcumin, we won’t discourage them.”

RELATED: 8 Foods to Eat During an Ulcerative Colitis Flare

How Much Turmeric Do You Need to Consume?

There is only a small amount of curcumin in turmeric. And studies show that the plant chemical is not well absorbed by the body, according to a review published in October 2017 in the journal Foods. You’d have to consume a lot of turmeric to reach levels that have been used in studies.

On the other hand, since it’s not yet clear what the optimal dose of curcumin is, consuming turmeric through diet may still offer some benefit. Combining turmeric with black pepper seems to significantly enhance absorption.

Piperine, black pepper’s signature compound, can boost absorption of turmeric by 2,000 percent, according to the Foods research review.

To get more turmeric in your diet, you can generously sprinkle the spice on:

• Scrambled eggs and frittatas
• Roasted vegetables
• Rice
• Curries
• Soups
• Oatmeal or cream of wheat
• Smoothies
• Tomato sauce

People with ulcerative colitis can also add the spice to hot water to make turmeric tea or to hot milk for turmeric lattes if they are not lactose intolerant.

If you want to go the supplement route, Cavagnoro advises not going above 3,000 mg of curcumin per day. “As with any supplement, if you take too much you may have side effects,” she explains.

High doses or long-term use of turmeric may cause gastrointestinal upset for some people, says the Mayo Clinic.

Large doses of curcumin also act as a blood thinner, according to the Crohn’s & Colitis Foundation. And they point out that the safety of taking curcumin during pregnancy is unknown.

Curcumin can also interact with certain medications, according to a report published July 2017 in the journal American Family Physician. So if you’re taking any prescription or over-the-counter medications, check in with your doctor or pharmacist before starting on a turmeric or curcumin supplement.

Both turmeric and curcumin are widely available in capsule, fluid extract, or tincture form, with a range of recommended dosages.

While you can’t believe all the claims you see on the bottles, there’s enough evidence to suggest that the excitement over turmeric isn’t just hype.

“This is the only supplement thus far that has good randomized control trial data to show some benefit to patients with UC,” Cavagnaro says. “While we study things like probiotics, fish oil, aloe vera juice, and antioxidants, curcumin remains at this time the only supplement with actual data on efficacy and implications for clinical practice.”

By subscribing you agree to the Terms of Use and Privacy Policy.

5 Ulcerative Colitis Complications

Extraintestinal complications — those that exist outside the intestines — can overshadow symptoms in your bowels, making UC tricky to diagnose. They are…

By Heidi Tyline KingJune 6, 2023

6 Need-to-Know Nutrients for Ulcerative Colitis

People with ulcerative colitis (UC) may have a hard time getting the nutrients they need. Find out what nutrient deficiencies can come with UC and how…

By Jennifer WarnerJune 5, 2023

8 Ways to Prevent Osteoporosis if You Have Ulcerative Colitis

If you take steroids for ulcerative colitis, you might have an increased risk of osteoporosis or low bone density. Here’s how to keep your bones strong…

By Brian P. DunleavyJune 2, 2023

10 Things to Know About Biologics for Ulcerative Colitis

Biologic medication for ulcerative colitis may work when other treatments fail. Learn 10 important facts about biologic therapy before you start.

By Chris Iliades, MDJune 1, 2023

Best Meal Delivery Kits for People With Ulcerative Colitis

These online food services, which include lots of fruits and vegetables and plant-based proteins, are great options for people with ulcerative colitis…

By Blake MillerMay 26, 2023

The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials

1. Magro F., Gionchetti P., Eliakim R., Ardizzone S., Armuzzi A., Barreiro-de Acosta M., Burisch J., Gecse K.B., Hart A. L., Hindryckx P., et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J. Crohn’s Colitis. 2017;11:649–670. doi: 10.1093/ecco-jcc/jjx008. [PubMed] [CrossRef] [Google Scholar]

2. Stapley S.A., Rubin G.P., Alsina D., Shephard E.A., Rutter M.D., Hamilton W.T. Clinical features of bowel disease in patients aged <50 years in primary care: A large case-control study. Br. J. Gen. Pract. 2017;67:e336–e344. doi: 10.3399/bjgp17X690425. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Ilhara S., Hirata Y., Koike K. TGF-β in inflammatory bowel disease: A key regulator of immune cells, epithelium and the intestinal microbiota. J. Gastroenterol. 2017;52:777–787. doi: 10.1007/s00535-017-1350-1. [PubMed] [CrossRef] [Google Scholar]

4. D’Haens G.R., Sartor R.B., Silverberg M.S., Petersson J., Rutgeerts P. Future directions in inflammatory bowel disease management. J. Crohn’s Colitis. 2014;8:726–734. doi: 10.1016/j.crohns.2014.02.025. [PubMed] [CrossRef] [Google Scholar]

5. Kawalec P., Malinowski K.P. Indirect health costs in ulcerative colitis and Crohn’s disease: A systematic review and meta-analysis. Expert Rev. Pharm. Outcomes Res. 2015;15:253–266. doi: 10.1586/14737167.2015.1011130. [PubMed] [CrossRef] [Google Scholar]

6. Harbord M., Eliakim R., Bettenworth D., Karmiris K., Katsanos K., Kopylov U., Kucharzik T., Molnár T., Raine T., Sebastian S., et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management. J. Crohn’s Colitis. 2017;11:769–784. doi: 10.1093/ecco-jcc/jjx009. [PubMed] [CrossRef] [Google Scholar]

7. Ben-Horin S., Mao R., Chen M. Optimizing biologic treatment in IBD: Objective measures, but when, how and how often? BMC Gastroenterol. 2015;15:178. doi: 10.1186/s12876-015-0408-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Munkholm P., Langholz E., Davidsen M., Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut. 1994;35:360–362. doi: 10.1136/gut.35.3.360. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

9. Faubion W.A., Jr., Loftus E.V., Jr., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology. 2001;121:255–260. doi: 10.1053/gast.2001.26279. [PubMed] [CrossRef] [Google Scholar]

10. Ho G.T., Chiam P., Drummond H., Loane J., Arnott I.D., Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: Analysis of a 5-year UK inception cohort. Aliment. Pharmacol. Ther. 2006;24:319–330. doi: 10.1111/j.1365-2036.2006.02974.x. [PubMed] [CrossRef] [Google Scholar]

11. Li J., Wang F., Zhang H.J., Sheng J.Q., Yan W.F., Ma M.X., Fan R.Y., Gu F., Li C.F., Chen D.F., et al. Corticosteroid therapy in ulcerative colitis: Clinical response and predictors. World J. Gastroenterol. 2015;21:3005–3015. doi: 10.3748/wjg.v21.i10.3005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

12. Zhou H., Beevers S.C., Huang S. Targets of curcumin. Curr. Cancer Drug Targets. 2012;12:332–347. doi: 10.2174/138945011794815356. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Kocaadam B., Sanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit. Rev. Food Sci. Nutr. 2017;57:2889–2895. doi: 10.1080/10408398.2015.1077195. [PubMed] [CrossRef] [Google Scholar]

14. Gupta S.C., Patchva S., Koh W., Aggarwal B.B. Discovery of curcumin, a component of the golden spice, and its miraculous biological activities. Clin. Exp. Pharmacol. Physiol. 2012;39:283–299. doi: 10.1111/j.1440-1681.2011.05648.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

15. Gupta S.C., Prasad S., Kim J.H., Patchva S., Webb L.J., Priyadarsini I.K., Aggarwal B.B. Multitargeting by curcumin as revealed by molecular interaction studies. Nat. Prod. Rep. 2011;2011:1937–1955. doi: 10.1039/c1np00051a. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Baliga M.S., Joseph N., Venkataranganna M.V., Saxena A., Ponemone V., Fayad R. Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: Preclinical and clinical observations. Food Funct. 2012;3:1109–1117. doi: 10.1039/c2fo30097d. [PubMed] [CrossRef] [Google Scholar]

17. Taylor R.A., Leonard M.C. Curcumin for inflammatory bowel disease: A review of human studies. Altern. Med. Rev. 2011;16:152–156. [PubMed] [Google Scholar]

18. Khalaf H., Jass J., Olsson E.P. Differential cytokine regulation by NF-κB and AP-1 in Jurkat T-cells. BMC Immunol. 2010;11:26. doi: 10.1186/1471-2172-11-26. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

19. Hutton B., Salanti G., Caldwell D.M., Chaimani A., Schmid C.H., Cameron C., Ioannidis J.P., Straus S., Thorlund K., Jansen J.P., et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann. Intern. Med. 2015;162:777–784. doi: 10.7326/M14-2385. [PubMed] [CrossRef] [Google Scholar]

20. O’Connor D., Green S., Higgins P.T.J. Chapter 5: Defining the review question and developing criteria for including studies. In: Higgins J.P.T., Greeen S., editors. Cochrane Handbook for Systematic Review A of Interventions Version 5.0. The Cochrane Collaboration; London, UK: 2008. [Google Scholar]

21. Higgins J.P.T., Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Updated. The Cochrane Collaboration; London, UK: 2011. [Google Scholar]

22. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., McQuay H.J. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control. Clin. Trials. 1996;17:1–12. doi: 10.1016/0197-2456(95)00134-4. [PubMed] [CrossRef] [Google Scholar]

23. Shapira S., Leshno A., Katz D., Maharshak N., Hevroni G., Jean-David M., Kraus S., Galazan L., Aroch I. , Kazanov D., et al. Of mice and men: A novel dietary supplement for the treatment of ulcerative colitis. Ther. Adv. Gastroenterol. 2018;11:1–10. doi: 10.1177/1756283X17741864. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

24. Suskind D.L., Wahbeh G., Burpee T., Cohen M., Christie D., Weber W. Tolerability of curcumin in pediatric inflammatory bowel disease: A forced dose titration study. J. Pediatric Gastroenterol. Nutr. 2013;56:277. doi: 10.1097/MPG.0b013e318276977d. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

25. Atkinson R.J., Hunter J.O. Double blind, placebo controlled randomized trial of Curcuma extract in the treatment of steroid dependent inflammatory bowel disease. Gastroenterology. 2003;124:A205. doi: 10.1016/S0016-5085(03)81031-4. [CrossRef] [Google Scholar]

26. Banerjee R., Medaboina K., Boramma G.G., Amsrala S., Reddy D.N. Novel bio-enhanced curcumin with mesalamine forinduction of remission in mild to moderate ulcerative colitis. Gastroenterology. 2017;152:S587. doi: 10.1016/S0016-5085(17)32111-X. [CrossRef] [Google Scholar]

27. Santos L.R. Master’s Thesis. UFG-Faculdade de Nutrição; Goiânia, Brazil: 2017. Perfil Inflamatório de Pacientes com Colite Ulcerativa em uso de Cúrcuma Longa; p. 34. [Google Scholar]

28. Hanai H., Iida T., Takeuchi K., Watanabe F., Maruyama Y., Andoh A., Tsujikawa T., Fujiyama Y., Mitsuyama K., Sata M., et al. Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 2006;4:1502–1506. doi: 10.1016/j.cgh.2006.08.008. [PubMed] [CrossRef] [Google Scholar]

29. Singla V., Pratap Mouli V., Garg S.K., Rai T., Choudhury B.N., Verma P., Deb R., Tiwari V., Rohatgi S., Dhingra R., et al. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis—A randomized, placebo-controlled, pilot study. J. Crohn’s Colitis. 2014;8:208–214. doi: 10.1016/j.crohns.2013.08.006. [PubMed] [CrossRef] [Google Scholar]

30. Lang A., Salomon N., Wu J.C., Kopylov U., Lahat A., Har-Noy O., Ching J.Y., Cheong P.K., Avidan B., Gamus D., et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin. Gastroenterol. Hepatol. 2015;13:1444–1449. doi: 10.1016/j.cgh.2015.02.019. [PubMed] [CrossRef] [Google Scholar]

31. Masoodi M., Mahdiabadi M.A., Mokhtare M., Agah S., Kashani A.H., Rezadoost A.M., Sabzikarian M., Talebi A., Sahebkar A. The efficacy of curcuminoids in improvement of ulcerative colitis symptoms and patients’self-reported well-being: A randomized double-blind controlled trial. J. Cell. Biochem. 2018;119:9552–9559. doi: 10.1002/jcb.27273. [PubMed] [CrossRef] [Google Scholar]

32. Kedia S., Bhatia V., Thareja S., Garg S., Mouli V.P., Bopanna S., Tiwari V., Makharia G., Ahuja V. Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial. World J. Gastrointest. Pharmacol. Ther. 2017;8:147–154. doi: 10.4292/wjgpt.v8.i2.147. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

33. Sadeghi N., Mansoori A., Shayesteh A., Hashemi S.J. The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis. Phytother. Res. 2019;34:1123–1133. doi: 10.1002/ptr.6581. [PubMed] [CrossRef] [Google Scholar]

34. Yallapu M.M., Jaggi M., Chauhan S.C. Curcumin nanoformulations: A future nanomedicine for cancer. Drug Discov. Today. 2012;17:71–80. doi: 10.1016/j.drudis.2011.09.009. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

35. European Food Safety Authority (EFSA) Refined exposure assessment for curcumin (E 100) EFSA J. 2014;12:3876. doi: 10.2903/j.efsa.2014.3876. [CrossRef] [Google Scholar]

36. JECFA Curcumin. (Prepared by Ivan Stankovic). Chemical and Technical Assessment Compendıum Addendum 11/Fnp 52 Add.11/29. Monographs. 2014;1:417. [Google Scholar]

37. Lao C.D., Ruffin M.T., Normolle D., Heath D.D., Murray S.I., Bailey J.M., Boggs M.E., Crowell J., Rock C.L., Brenner D.E. Dose escalation of a curcuminoid formulation. BMC Complement. Altern. Med. 2006;6:10. doi: 10.1186/1472-6882-6-10. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

38. Schiborr C., Kocher A., Behnam D., Jandasek J., Toelstede S., Frank J. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol. Nutr. Food Res. 2014;58:516–527. doi: 10.1002/mnfr.201300724. [PubMed] [CrossRef] [Google Scholar]

39. Ohno M., Nishida A., Sugitani Y., Nishino K., Inatomi O., Sugimoto M., Kawahara M., Andoh A. Nanoparticle curcumin ameliorates experimental colitis via modulation of gut microbiota and induction of regulatory T cells. PLoS ONE. 2017;12:e0185999. doi: 10.1371/journal.pone.0185999. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

40. Jamwal R. Bioavailable curcumin formulations: A review of pharmacokinetic studies in healthy volunteers. J. Integr. Med. 2018;16:367–374. doi: 10.1016/j.joim.2018.07.001. [PubMed] [CrossRef] [Google Scholar]

41. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64:353–356. doi: 10.1055/s-2006-957450. [PubMed] [CrossRef] [Google Scholar]

42. Li Q., Zhai W., Jiang Q., Huang R., Liu L., Dai J., Gong W., Du S., Wu Q. Curcumin-piperine mixtures in self-microemulsifying drug delivery system for ulcerative colitis therapy. Int. J. Pharm. 2015;490:22–31. doi: 10.1016/j.ijpharm.2015.05.008. [PubMed] [CrossRef] [Google Scholar]

43. Kumar G., Mittal S., Sak K., Tuli H.S. Molecular mechanisms underlying chemopreventive potencial of curcumin: Current challenges and future perspectives. Life Sci. J. 2016;148:313–328. doi: 10.1016/j.lfs.2016.02.022. [PubMed] [CrossRef] [Google Scholar]

44. Platel K., Srinivasan K. Studies on the influence of dietary spices on food transit time in experimental rats. Nutr. Res. 2001;21:1309–1314. doi: 10.1016/S0271-5317(01)00331-1. [CrossRef] [Google Scholar]

45. Tanko H., Carrier D.J., Duan L., Clausen E. Pre-and post-harvest processing of medicinal plants. Plant Genet. Resour. 2005;3:304–313. doi: 10.1079/PGR200569. [CrossRef] [Google Scholar]

46. Figueiredo A.C., Barroso J.G., Pedro L.G., Scheffer J.J. Factors affecting secondary metabolite production in plants: Volatile components and essential oils. Flavour Fragr. J. 2008;23:213–226. doi: 10.1002/ffj.1875. [CrossRef] [Google Scholar]

47. Choudhury B.U., Nath A., Hazarika S., Ansari M.A., Buragohain J., Mishra D. Effects of pre-harvest soil management practices and post-harvest processing on phytochemical qualities of turmeric (Curcuma longa) Indian J. Agric. Sci. 2017;87:1002–1007. [Google Scholar]

Turmeric increases the effectiveness of the treatment of intestinal diseases

News

Over the past decade, there has been significant progress in the use of herbal medicines for the treatment of inflammatory bowel disease, as well as the integration of complementary and natural medicine, although the effectiveness of some plants has been proven 2000 years ago by Chinese medicine. Researchers at Tel Hashomer Medical Center have found that curcumin, the active ingredient in turmeric, increases the effectiveness of medical treatments for colitis and leads to longer and better clinical remissions.

Turmeric, widely used in the cuisine of many peoples of the world, has been known for centuries as a medicinal plant. In the middle of the last century, one of its main active ingredients, curcumin, was derived from turmeric, a strong-smelling, yellow-orange substance that has become something of a miracle in so-called herbal medicine. Since then, several studies have been conducted in medical centers around the world, which traced the effect of the substance on the treatment of inflammatory and neurological diseases, as well as on certain types of cancer, such as breast cancer, colon cancer, prostate cancer.

Since 2006, there has been extensive research into the effects of curcumin on inflammatory bowel disease. including the first human controlled trial investigating the efficacy of curcumin treatment in maintaining clinical remission in patients with ulcerative colitis. The results clearly showed that patients who took curcumin along with medication maintained remission longer and better than patients who took medication alone.

The results formed the basis of research initiated at the Institute of Gastroenterology of the Medical Center. Chaima Sheeba (Tel Hashomer), Dr. Alon Lang and Dr. Shomron Ben-Horin. The purpose of the study is to investigate the possibility of using carcumin in the treatment of patients suffering from acute intestinal inflammation.

The first stage was a series of laboratory tests that combined curcumin with conventional medications to treat ulcerative colitis. From the results obtained, it became clear that curcumin is effective not only at suppressing the mechanisms that contribute to the development of inflammation, but when combined with drugs, it gives a higher efficiency than drugs and curcumin alone. Laboratory studies established the principle of integrated patient care, which was tested during the study.

Treatment of colitis

Three “steps” have been adopted to refer to drugs used to treat ulcerative colitis. Many patients who do not respond to “first line” medications need “second line” medications, steroids, or drugs to suppress the immune system. But these medications have side effects and known risks. Because of this, many patients (and physicians) shy away from switching to their regular use. The purpose of the initiated study was to investigate the effect of combination therapy with curcumin. The researchers were trying to find out if the combination of drugs and curcumin actually achieves clinical remission before using second-line drugs and prevents the need to increase the stage of drug treatment. Patients suffering from acute inflammation and taking the maximum dose of “first step” drugs were selected for the study.

Today, two years after the start of recruitment for the study, data analysis indicates very encouraging results. Combination treatment with curcumin resulted in remission or significant clinical improvement in a significant number of patients. The improvement in the clinical picture in the study group was significantly higher than in the control group. In addition, in the study group, an improvement in the condition of the intestinal mucosa was also observed. These interim results were presented at the Association of Gastroenterologists conference and received favorable feedback from the medical community. Other medical research centers have joined the study in recent months. Patient selection is currently underway in Europe and Hong Kong.

Curcumin is effective in ulcerative colitis | Ukrainian Medical Chasopis

July 31, 2012 about 17

Kotikovich Yu.S.

Key words:

inflammatory bowel disease,

intestine,

turmeric,

curcumin,

Nonspecific ulcerative colitis

Gastroenterology

Summary

It helps maintain remission

Nonspecific ulcerative colitis (UC) is a chronic inflammatory disease of the large intestine characterized by episodes of exacerbation and remission. Currently, insufficient knowledge has been accumulated about the effectiveness and safety of using traditional or alternative methods of treating this pathology. A group of independent experts of the Cochrane Collaboration, led by Dr. Sushil Kumar from the University of Minnesota, USA, evaluated the effectiveness of drugs based on the plant Curcuma longa L. and came to the conclusion that they can be an integral part of complex therapy for NUC to maintain the stage of remission of this disease.

Curcuma longa L. is a herbaceous plant of the ginger family. Its leaves contain a large amount of curcumin, a biologically active phenolic compound. It has antioxidant, antiplatelet, anti-inflammatory and fungicidal effects. Due to its anti-inflammatory properties, preparations containing curcumin are used in the treatment of rheumatoid arthritis, esophagitis and postoperative inflammatory processes.

For the systematic review, investigators analyzed the Medline and Embase databases, as well as the Cochrane Central Register of Controlled Trials and the Cochrane Inflammatory Bowel Disease Trial Register as of 11 July 2012. Randomized placebo-controlled trials investigating the efficacy of curcumin were included in the systematic review. with UC. Participants (of any gender and age) were in remission at the start of the trial.

Only one study met the criteria. Its participants (89 people) were divided into two groups. Patients of the 1st group (n=45) took drugs with curcumin orally (2 g/day for 6 months), the 2nd (n=44) – placebo. All participants received treatment including sulfasalazine or mesalazine. After 6 months, relapse of the disease was observed in 4% of participants in group 1 and in 18% of participants in group 2 (relative risk (RR) 0.24; 95% confidence interval (CI) 0.05–1.09; p=0 .06). 12 months after the start of the study, there were no statistically significant differences in the frequency of relapses in participants in the 1st (22%) and 2nd (32%) groups (RR 0.70; CI 0.35–1.40; p=0 ,31). The side effect of the study drug was observed only in 7 participants of the 1st group and manifested itself in the form of abdominal pain, nausea and transient arterial hypertension.